Literature DB >> 28000098

Insulin Formulation Characterization-the Thioflavin T Assays.

Morten Schlein1.   

Abstract

The insulin molecule was discovered in 1921. Shortly thereafter, its propensity towards amyloid fibril formation, fibrillation, was observed and described in the literature as a "precipitate." In the past decades, the increased incidence of type 2 diabetes has reached global epidemic proportions. This has emphasized the demands for both insulin production and the development of modern insulin products for unmet medical needs. Bringing such new insulin drug products to the market for the benefit of patients requires that many CMC-related processes are understood, described, and controlled. One potential undesired process is insulin fibril formation. The compound thioflavin T (ThT) is known as a fluorescent probe for amyloid fibrils. As such, ThT is utilized in a versatile research assay in microtiter plate format, the ThT assay. This review will describe an experimental set-up using not only a ThT microtiter plate assay but also two orthogonal methods. The use of the ThT assay in research and characterization of insulin analogues, as well as formulations of insulin, is described by cases drawn from the scientific literature and patents. The ThT assay is compared to other physical stability tests and in conclusion the advantages and limitations of the assay are compared.

Entities:  

Keywords:  amyloid fibril formation; insulin; peptide and small protein drug product formulation; physical stability; thioflavin T fluorescence

Mesh:

Substances:

Year:  2016        PMID: 28000098     DOI: 10.1208/s12248-016-0028-6

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  99 in total

1.  The effect of mutations on the structure of insulin fibrils studied by Fourier transform infrared (FTIR) spectroscopy and electron microscopy.

Authors:  Liza Nielsen Garriques; Sven Frokjaer; John F Carpenter; Jens Brange
Journal:  J Pharm Sci       Date:  2002-12       Impact factor: 3.534

2.  Probing the mechanism of insulin fibril formation with insulin mutants.

Authors:  L Nielsen; S Frokjaer; J Brange; V N Uversky; A L Fink
Journal:  Biochemistry       Date:  2001-07-27       Impact factor: 3.162

3.  The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting.

Authors:  Jesper Søndergaard Pedersen; Dantcho Dikov; James L Flink; Hans Aage Hjuler; Gunna Christiansen; Daniel Erik Otzen
Journal:  J Mol Biol       Date:  2005-11-09       Impact factor: 5.469

Review 4.  Time-resolved biophysical methods in the study of protein folding.

Authors:  K W Plaxco; C M Dobson
Journal:  Curr Opin Struct Biol       Date:  1996-10       Impact factor: 6.809

Review 5.  Toward understanding insulin fibrillation.

Authors:  J Brange; L Andersen; E D Laursen; G Meyn; E Rasmussen
Journal:  J Pharm Sci       Date:  1997-05       Impact factor: 3.534

6.  Characterization of the R-state insulin hexamer and its derivatives. The hexamer is stabilized by heterotropic ligand binding interactions.

Authors:  M L Brader; N C Kaarsholm; R W Lee; M F Dunn
Journal:  Biochemistry       Date:  1991-07-09       Impact factor: 3.162

7.  Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death.

Authors:  Fanling Meng; Peter Marek; Kathryn J Potter; C Bruce Verchere; Daniel P Raleigh
Journal:  Biochemistry       Date:  2008-05-06       Impact factor: 3.162

Review 8.  Evolution of insulin: from human to analog.

Authors:  Joseph M Tibaldi
Journal:  Am J Med       Date:  2014-10       Impact factor: 4.965

Review 9.  A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations.

Authors:  M Evans; P M Schumm-Draeger; J Vora; A B King
Journal:  Diabetes Obes Metab       Date:  2011-08       Impact factor: 6.577

10.  Novel covalently linked insulin dimer engineered to investigate the function of insulin dimerization.

Authors:  Tine N Vinther; Mathias Norrman; Holger M Strauss; Kasper Huus; Morten Schlein; Thomas Å Pedersen; Thomas Kjeldsen; Knud J Jensen; František Hubálek
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  5 in total

1.  Degradation of insulin amyloid by antibiotic minocycline and formation of toxic intermediates.

Authors:  Wakako Mori; Keisuke Yuzu; Nadine Lobsiger; Hideo Nishioka; Hisako Sato; Terumasa Nagase; Keiichi Iwaya; Mikael Lindgren; Tamotsu Zako
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

2.  Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications.

Authors:  Catherine M Meis; Abigail K Grosskopf; Santiago Correa; Eric A Appel
Journal:  J Vis Exp       Date:  2021-02-07       Impact factor: 1.355

3.  Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls.

Authors:  Lotte Simonsen; Jesper Lau; Thomas Kruse; Tingqing Guo; Jim McGuire; Jacob Fuglsbjerg Jeppesen; Kristoffer Niss; Per Sauerberg; Kirsten Raun; Charlotta Dornonville de la Cour
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

4.  Amyloid-like staining property of RADA16-I nanofibers and its potential application in detecting and imaging the nanomaterial.

Authors:  Yongzhu Chen; Yusi Hua; Wensheng Zhang; Chengkang Tang; Yan Wang; Yujun Zhang; Feng Qiu
Journal:  Int J Nanomedicine       Date:  2018-04-23

5.  Rational Development of Stable PYY3-36 Peptide Y2 Receptor Agonists.

Authors:  Christian Poulsen; Marie Østergaard Pedersen; Per-Olof Wahlund; Annika Sjölander; Jens Kaalby Thomsen; Kilian W Conde-Frieboes; Johan F Paulsson; Birgitte S Wulff; Søren Østergaard
Journal:  Pharm Res       Date:  2021-07-16       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.